Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic expected Q1 2027 (shifted from the previously estimated Q4 2026) Availability updated: Retatrutide remains investigational
Contraindicated in MTC or MEN2 history As with other GLP-1 agonists, Retatrutide is not appropriate for patients with personal or family history of medullary thyroid carcinoma or MEN2
The 28% triglyceride reduction, 6.8 mmHg blood pressure drop, and superior weight loss all suggest cardiovascular benefits that may exceed the competitors
Consuming foods that boost glutathione helps your skin heal, brighten, and detoxify naturally over time
US$ 20.29
US$ 26.18
US$ 20.71
US$ 24.05
US$ 28.11
US$ 24.74
US$ 22.42
